Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.

Jan 14, 2010, 13:00 ET from Sword Diagnostics Inc.

CHICAGO, Jan. 14 /PRNewswire/ -- Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays.  The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.  These increases in performance could aid researchers in basic and clinical science research, drug discovery, and clinical diagnostics development.

"We find the resolution at low concentrations to be an exciting benefit in our ovarian cancer and infertility research," said Professor Judith Luborsky, Ph.D., Associate Dean for Research, College of Health Sciences, Director, Laboratory for Ovarian Cancer Research and Director, Rush Proteomics & Biomarkers Core Research Facility at Rush University Medical Center.  "The technology was easily integrated into existing tests with minimal optimization and provided excellent improvements.  In fact, we have included Sword technology in several grants we are currently applying for."

"We are pleased with the positive reception our technology has received from the market. The key opinion leaders have found it particularly useful for highly sensitive ELISAs," said Dave Dingott, founder and CEO of Sword Diagnostics.  "The Raman plate reader allows current ELISA users to continue using their 96-well format, making conversion to our technology extremely simple and cost effective."

About Sword Diagnostics

Sword Diagnostic's mission is to improve existing immunoassays by providing additional sensitivity to currently available antibody-based test as well as allowing researchers to monitor new markers that are not readily detectable with current technology.  This may lead to earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer's disease.  Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.

Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays.  The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry.  The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.  


SOURCE Sword Diagnostics Inc.